Natco Pharma Ltd
NSE:NATCOPHARM

Watchlist Manager
Natco Pharma Ltd Logo
Natco Pharma Ltd
NSE:NATCOPHARM
Watchlist
Price: 1 371.5 INR -1.23% Market Closed
Market Cap: 245.6B INR
Have any thoughts about
Natco Pharma Ltd?
Write Note

Relative Value

The Relative Value of one NATCOPHARM stock under the Base Case scenario is 915.4 INR. Compared to the current market price of 1 371.5 INR, Natco Pharma Ltd is Overvalued by 33%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

NATCOPHARM Relative Value
Base Case
915.4 INR
Overvaluation 33%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
49
vs Industry
23
Median 3Y
4.6
Median 5Y
5.6
Industry
2.5
Forward
4.8
vs History
85
vs Industry
28
Median 3Y
16.8
Median 5Y
25.3
Industry
21.8
Forward
12.6
vs History
69
vs Industry
23
Median 3Y
17.8
Median 5Y
21.2
Industry
16.1
vs History
42
vs Industry
21
Median 3Y
20.9
Median 5Y
17.6
Industry
23.8
vs History
38
vs Industry
20
Median 3Y
3
Median 5Y
3.1
Industry
2.1
vs History
49
vs Industry
24
Median 3Y
4.3
Median 5Y
5.1
Industry
2.7
Forward
4.4
vs History
57
vs Industry
33
Median 3Y
5.7
Median 5Y
6.4
Industry
5.2
vs History
84
vs Industry
31
Median 3Y
12.9
Median 5Y
17.5
Industry
13.5
Forward
8.8
vs History
85
vs Industry
32
Median 3Y
14.2
Median 5Y
21.2
Industry
16.8
Forward
9.4
vs History
71
vs Industry
25
Median 3Y
16.6
Median 5Y
19.6
Industry
15.2
vs History
53
vs Industry
19
Median 3Y
16.7
Median 5Y
18.7
Industry
19.3
vs History
11
vs Industry
19
Median 3Y
3.2
Median 5Y
3.3
Industry
1.9

Multiples Across Competitors

NATCOPHARM Competitors Multiples
Natco Pharma Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Natco Pharma Ltd
NSE:NATCOPHARM
245.6B INR 5.4 12.6 9.4 10.2
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
756.3B USD 18.5 90.4 48.5 54.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK 10.2 29 20.2 23
US
Johnson & Johnson
NYSE:JNJ
349.7B USD 4 23.8 11.5 15
US
Merck & Co Inc
NYSE:MRK
251.6B USD 4 20.7 10.5 12.5
CH
Roche Holding AG
SIX:ROG
200.1B CHF 3.4 17.4 9.8 11.6
UK
AstraZeneca PLC
LSE:AZN
162.1B GBP 4.1 31.5 169.4 253.9
CH
Novartis AG
SIX:NOVN
171.5B CHF 3.8 10.8 9.4 13.1
US
Pfizer Inc
NYSE:PFE
151.4B USD 2.5 35.6 10.6 16
P/S Multiple
Revenue Growth P/S to Growth
IN
Natco Pharma Ltd
NSE:NATCOPHARM
Average P/S: 382 942.5
5.4
-5%
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
4 211 733
22%
194 879.4
US
Eli Lilly and Co
NYSE:LLY
18.5
109%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
578.3
29%
19.9
DK
Novo Nordisk A/S
CSE:NOVO B
10.2
77%
0.1
US
Johnson & Johnson
NYSE:JNJ
4
13%
0.3
US
Merck & Co Inc
NYSE:MRK
4
20%
0.2
CH
Roche Holding AG
SIX:ROG
3.4
15%
0.2
UK
AstraZeneca PLC
LSE:AZN
4.1
35%
0.1
CH
Novartis AG
SIX:NOVN
3.8
17%
0.2
US
Pfizer Inc
NYSE:PFE
2.5
10%
0.3
P/E Multiple
Earnings Growth P/E to Growth
IN
Natco Pharma Ltd
NSE:NATCOPHARM
Average P/E: 30.2
12.6
-31%
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
90.4
446%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
29
86%
0.3
US
Johnson & Johnson
NYSE:JNJ
23.8
-23%
N/A
US
Merck & Co Inc
NYSE:MRK
20.7
7 300%
0
CH
Roche Holding AG
SIX:ROG
17.4
54%
0.3
UK
AstraZeneca PLC
LSE:AZN
31.5
177%
0.2
CH
Novartis AG
SIX:NOVN
10.8
31%
0.3
US
Pfizer Inc
NYSE:PFE
35.6
719%
0
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
Natco Pharma Ltd
NSE:NATCOPHARM
Average EV/EBITDA: 414.6
9.4
-42%
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
48.5
195%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
151%
25.5
DK
Novo Nordisk A/S
CSE:NOVO B
20.2
84%
0.2
US
Johnson & Johnson
NYSE:JNJ
11.5
14%
0.8
US
Merck & Co Inc
NYSE:MRK
10.5
331%
0
CH
Roche Holding AG
SIX:ROG
9.8
23%
0.4
UK
AstraZeneca PLC
LSE:AZN
169.4
64%
2.7
CH
Novartis AG
SIX:NOVN
9.4
8%
1.2
US
Pfizer Inc
NYSE:PFE
10.6
31%
0.3
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
Natco Pharma Ltd
NSE:NATCOPHARM
Average EV/EBIT: 1 811.2
10.2
-46%
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.2
211%
0.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
675%
26.2
DK
Novo Nordisk A/S
CSE:NOVO B
23
83%
0.3
US
Johnson & Johnson
NYSE:JNJ
15
28%
0.5
US
Merck & Co Inc
NYSE:MRK
12.5
675%
0
CH
Roche Holding AG
SIX:ROG
11.6
28%
0.4
UK
AstraZeneca PLC
LSE:AZN
253.9
131%
1.9
CH
Novartis AG
SIX:NOVN
13.1
58%
0.2
US
Pfizer Inc
NYSE:PFE
16
68%
0.2

See Also

Discover More
Back to Top